Mercado U

Language: Spanish
References: 8
Page: 48-56
PDF size: 349.32 Kb.

ABSTRACT

For many years, a connection between systemic lupus erythematosus and viral infection has been reported. Viruses such as Epstein-Barr virus, cytomegalovirus, parvovirus B-19 and now severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, are linked to a high risk of autoimmune diseases, including systemic lupus erythematosus. Since March 2020 COVID-19 pandemic challenged public health system and the most effective way to reduce COVID-19 infection was immunization. In less than 12 months COVID-19 immunization began. The messenger RNA (Pfizer and Moderna) vaccines were frequently used. S (spike) protein was the primary target to generate neutralizing antibodies in more than 95% of cases. However, immunological phenomena and autoimmune diseases were reported before 30 days following COVID-19 vaccine administration. In this case-based review, the author searched for subjects with a diagnosis of lupus erythematosus following COVID-19 infection or COVID-19 vaccination. Clinical manifestations, personal and family history of autoimmune diseases, number of autoantibodies, and treatment were investigated. Lupus erythematosus activity was measured using Mex-SLEDAI. A clinical history score higher than 7 was considered active lupus erythematosus.

REFERENCES

1. Li C, He Q, Qiang H, Liu J. Overview of the pathogenesisof COVID-19 (Review). Exp Ther Med 2021; 3: 1011. doi:10.3892/etm.2021.10444

2. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis.Nature Rev Microbiol 2022; 20: 270-283. doi: 10.1038/s41579-022-00713-0

3. Mahmounia L, Roshan B, Reza JH, Mojtahedi Z, et al.Systemic lupus erythematosus following SARS-CoV-2 vaccination:a review of literature. J Nephropharmacol 2023;12: e10564. DOI: 10.34172/npj.2022.10564

4. Sharma C, Bayry J. High risk of autoimmune diseases afterCOVID-19. Nat Rev Rheumatol 2023; 19: 399-400. doi:10.1038/s41584-023-00964-y

5. Chang R, Yen-Tin CT, Shiow-Ing W, Yao-Min H, et al. Riskof autoimmune diseases in patients con COVID-19: a retrospectivecohort study. Clin Med 2023; 56: 101783. doi:10.1016/j.eclinm.2022.101783

6. Tesch F, Ehm F, Vivirito A, Wende D, et al. Incident autoimmunediseases in association with a SARS infection: amatched cohort study. Clin Rheumatol 2023; 42: 2905-2914. doi: 10.1007/s10067-023-06670-0

7. Lim SH, Ju HJ, Han JH, Lee WSL, Lee BS. Autoimmune andautoinflammatory connective tissue disorders followingCOVID-19. JAMA Netw Open 2023; 6: e2336120. doi:10.1001/jamanetworkopen.2023.36120

8. Guzman J, Cardiel MM, Arce-Salinas A, Sanchez-GuerreroJ, Alarcon-Segovia F. Measurement of disease activity insistémica lupus erythematosus. Prospective validation of3 clinical indices. J Rheumatol 1992; 19: 1551-8.